Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

26 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

ipilimumab Articles

Boost for Bristol-Myers as US FDA approves Yervoy for metastatic melanoma

28 March 2011

Bristol-Myers Squibb’s ipilimumab achieves Ph III endpoints in metastatic melanoma

23 March 2011

Bristol-Myers Squibb’s BLA for ipilimumab in melanoma delayed by US FDA

3 November 2010

Roche and Plexxikon’s PLX4032 shows 81% response in metastatic melanoma patients in Ph I trial

26 August 2010

Bristol-Myers Squibb files melanoma drug ipilimumab BLA; gets FDA priority review

19 August 2010

Combination treatment, including Bayer’s sorafenib, regimen not effective against advanced melanoma; B-MS’ ipilimumab good in MM

7 June 2010

Showing 1-6 of 6 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS